Artiva Biotherapeutics to Present AlloNK® Data at ISSjD 2026

SAN DIEGO, Sept. 23, 2026 /CourierPR/ -- Artiva Biotherapeutics, a clinical-stage biotechnology company based in San Diego, California, announced that it will present updated clinical data on its AlloNK® (also known as AB-101) therapy at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026), scheduled for September 29th to October 2nd at the Cité Internationale Universitaire de Paris. AlloNK® is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved natural killer (NK) cell therapy designed to enhance antibody-dependent cellular cytotoxicity for a range of antibodies, including anti-CD20 antibodies, and drive deep B-cell depletion.

AlloNK® has shown encouraging activity in multiple B-cell-driven autoimmune diseases, according to the company. The therapy is being evaluated in refractory rheumatoid arthritis (RA), Sjögren’s disease, systemic sclerosis, and myositis. Artiva plans to initiate a Phase 3 registrational trial of AlloNK® in refractory RA in the second half of 2026. The company is developing AlloNK® to drive deep B-cell depletion through a scalable, outpatient-administered treatment regimen compatible with community rheumatology settings.

The updated clinical data will be presented in an oral presentation at the ISSjD 2026 symposium. Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with debilitating autoimmune diseases. The company’s mission is to bring innovative treatments to patients in need, with AlloNK® being a key part of its strategy.

For more information on the presentation and other abstracts, interested parties can visit the ISSjD 2026 abstract book. Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with debilitating autoimmune diseases. The company’s forward-looking statements are based on the beliefs of its management and assumptions made by and information currently available to Artiva. These statements reflect the current views of Artiva with respect to future events and are subject to known and unknown risks and uncertainties.

Artiva Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.artivabio.com. The company’s forward-looking statements are subject to the risks and uncertainties described in the section titled “Risk Factors” in Artiva’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Artiva undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.